Skip to content

Neurophysiological and morphological studies on endogenous pruritic inhibition by thermal pain (Diffuse Pruritic Inhibitory Control, DPIC) in chronic pruritus patients and healthy controls

Neurophysiological and morphological studies on endogenous pruritic inhibition by thermal pain (Diffuse Pruritic Inhibitory Control, DPIC) in chronic pruritus patients and healthy controls

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00011008
Enrollment
200
Registered
2016-09-09
Start date
2019-10-15
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L29.8

Interventions

Group 1: Test arm: Conditioning by heat and cold pain Chronic pruritus patients and healthy controls will receive experimental pruritus stimuli in randomized fashion (cowhage, histamine or NaCl as a

Sponsors

Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with chronic pruritus and matched (age and gender) healthy controls

Exclusion criteria

Exclusion criteria: - maximal pruritus intensity <3 (VAS, 0-10) in the first two minutes after cowhage or histamine application - skin lesions in the testing site (e.g. erosions, infection) - neurological or severe psychiatric comorbidities according to the medical history - skin type = III (Fitzpatrick; Mediterranean and darker skin types are excluded due tot he lack of data in healthy controls) - allergy against the study substances - disease that prevents the participation in the study - use of medication that influences the perception of pruritus up to1 week prior to study start (e.g. antihistamines, pregabaline/gabapentine, opioids) - use of urea, polidocanol, capsaicin, topical steroids, topical keratolytica, exfoliatives, self-tanners, topical or systemic antihistamines, anticonvulsivants, sedatives up to 1 week prior to study start - systemic steroids up to 2 weeks prior to study start - topical or systemic immunmodulators, antidepressants, drugs against migraine up to 1 month prior to study start - non steroidal or other non-opioid pain killers up to 2 days prior to study start - use of cosmetics or skin care products on the study day - pregnant or breastfeeding women Healthy controls: - atopy - pruritus

Design outcomes

Primary

MeasureTime frame
Difference of the pruritus inhibition effect (duration and magnitude of pruritus reduction) by noxious heat/cold stimulation between healthy controls and chronic pruritus patients of various origins in different experimental models: A) cowhage (activation of mechano-sensitive C-fibers) B) histamine (activation of mechano-insensitive C-fibers) C) negative control NaCl: study participants receive saline instead of cowhage or histamine

Secondary

MeasureTime frame
a) Correlation between QST parameters and the pruritus inhibitory effect by thermal pain b) Delta of QST parameters before and after stimulation with Bite Away ® c) Correlation between the intraepidermal nerve fiber density and the magnitude of pruritus inhibition by thermal pain d) Correlation between psychological variables (assessed by standardized questionnaires) and the magnitude of pruritus inhibition by thermal pain

Countries

Germany

Contacts

Public ContactManuel Pereira

Komeptenzzentrum Chronischer Pruritus (KCP) und Klinik für Hautkrankheiten, Universitätsklinikum Münster

ManuelPedro.FernandesLoboPereira@ukmuenster.de0251-8356510

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026